

Aakash P Desai

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3805030/publications.pdf>

Version: 2024-02-01

51
papers

2,392
citations

706676

14
h-index

252626

46
g-index

51
all docs

51
docs citations

51
times ranked

5940
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. <i>Lancet</i> , The, 2020, 395, 1907-1918.	6.3	1,395
2	COVID-19 and Cancer: Lessons From a Pooled Meta-Analysis. <i>JCO Global Oncology</i> , 2020, 6, 557-559.	0.8	258
3	Financial toxicity of cancer treatment: Moving the discussion from acknowledgement of the problem to identifying solutions. <i>EClinicalMedicine</i> , 2020, 20, 100269.	3.2	102
4	Mortality in hospitalized patients with cancer and coronavirus disease 2019: A systematic review and meta-analysis of cohort studies. <i>Cancer</i> , 2021, 127, 1459-1468.	2.0	98
5	Crowdsourcing a crisis response for COVID-19 in oncology. <i>Nature Cancer</i> , 2020, 1, 473-476.	5.7	66
6	COVID-19 and Cancer. <i>JAMA Oncology</i> , 2021, 7, 1882.	3.4	42
7	Antibody-drug conjugates: A promising novel therapeutic approach in lung cancer. <i>Lung Cancer</i> , 2022, 163, 96-106.	0.9	35
8	Endpoints used in phase III randomized controlled trials of treatment options for COVID-19. <i>EClinicalMedicine</i> , 2020, 23, 100403.	3.2	32
9	Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-2019. <i>JAMA Network Open</i> , 2022, 5, e2216183.	2.8	27
10	The CoVIDâ€”TE risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVIDâ€”19. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2522-2532.	1.9	23
11	Hallmarks of RET and Co-occurring Genomic Alterations in <i>RET</i> -aberrant Cancers. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1769-1776.	1.9	23
12	Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600E Mutant Tumors. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 871-878.	1.9	23
13	Change in Reporting of USMLE Step 1 Scores and Potential Implications for International Medical Graduates. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 2015.	3.8	22
14	Financial toxicity in hematological malignancies: a systematic review. <i>Blood Cancer Journal</i> , 2022, 12, 74.	2.8	22
15	Association of a Remote Patient Monitoring (RPM) Program With Reduced Hospitalizations in Cancer Patients With COVID-19. <i>JCO Oncology Practice</i> , 2021, 17, e1293-e1302.	1.4	18
16	Immunological alternation in COVID-19 patients with cancer and its implications on mortality. <i>Oncolmmunology</i> , 2021, 10, 1854424.	2.1	18
17	Trends in Prices of Drugs Used to Treat Metastatic Nonâ€”Small Cell Lung Cancer in the US From 2015 to 2020. <i>JAMA Network Open</i> , 2022, 5, e2144923.	2.8	14
18	5-Fluorouracil Rechallenge After Cardiotoxicity. <i>American Journal of Case Reports</i> , 2020, 21, e924446.	0.3	13

#	ARTICLE	IF	CITATIONS
19	Category of evidence and consensus underlying National Comprehensive Cancer Network guidelines: Is there evidence of progress?. <i>International Journal of Cancer</i> , 2021, 148, 429-436.	2.3	12
20	Financial conflicts of interest among National Comprehensive Cancer Network clinical practice guideline panelists in 2019. <i>Cancer</i> , 2020, 126, 3742-3749.	2.0	11
21	Tumor Junction Burden and Antigen Presentation as Predictors of Survival in Mesothelioma Treated With Immune Checkpoint Inhibitors. <i>Journal of Thoracic Oncology</i> , 2021, , .	0.5	11
22	Prognostic value of hypoalbuminemia at diagnosis in <i>de novo</i> non-M3 acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 641-649.	0.6	10
23	Demographic and Socioeconomic Disparities Among Cancer Survivors in Clinical Trials Participation, USA, 2016â€“2018. <i>Journal of Cancer Education</i> , 2022, 37, 88-90.	0.6	9
24	A Case of Immunotherapy-Induced Colitis Complicated by Perforation and Treated with Infliximab Postoperatively. <i>Case Reports in Oncological Medicine</i> , 2019, 2019, 1-6.	0.2	8
25	Crowdsourcing in Crisis: Rising to the Occasion. <i>JCO Clinical Cancer Informatics</i> , 2020, 4, 551-554.	1.0	8
26	Quantifying risk factors for ischemic colitis: A nationwide, retrospective cohort study. <i>Indian Journal of Gastroenterology</i> , 2020, 39, 398-404.	0.7	8
27	Use of Real-World Electronic Health Records to Estimate Risk, Risk Factors, and Disparities for COVID-19 in Patients With Cancer. <i>JAMA Oncology</i> , 2021, 7, 227.	3.4	7
28	Cardiovascular risk management in cancer survivors: Are we doing it right?. <i>World Journal of Clinical Oncology</i> , 2021, 12, 144-149.	0.9	7
29	Assessing the benefits and harms of direct oral anticoagulants in patients with cancer for the prophylaxis and treatment of venous thromboembolism: a systematic review and meta-analysis. <i>Ecanermedalscience</i> , 2020, 14, 1091.	0.6	7
30	Fall in US cancer death rates: Time to pop the champagne?. <i>EclinicalMedicine</i> , 2020, 19, 100279.	3.2	6
31	Progress in molecular feature of smoldering mantle cell lymphoma. <i>Experimental Hematology and Oncology</i> , 2021, 10, 41.	2.0	6
32	Economic Cost and Sustainability of Oral Therapies in Precision Oncology. <i>JCO Oncology Practice</i> , 2022, 18, e1247-e1254.	1.4	6
33	Aligning Cancer Clinical Trials With Cancer Burden. <i>JAMA Oncology</i> , 2021, 7, 357.	3.4	5
34	Severity of Sars-Cov-2 Infection in Patients with Hematologic Malignancies: A COVID-19 and Cancer Consortium (CCC19) Registry Analysis. <i>Blood</i> , 2020, 136, 28-30.	0.6	5
35	Reversible Ocular Toxicity of Oxaliplatin: A Case Report. <i>Cureus</i> , 2019, 11, e4582.	0.2	5
36	Alteration of serum markers in COVIDâ€“19 and implications on mortality. <i>Clinical and Translational Medicine</i> , 2020, 10, e119.	1.7	4

#	ARTICLE	IF	CITATIONS
37	COVID-19 and Global Oncology: A Year in Review. JCO Global Oncology, 2021, 7, 797-801.	0.8	4
38	HER-2 Neu gene: A valuable therapeutic target in metastatic mucoepidermoid carcinoma. Journal of Oncology Pharmacy Practice, 2021, 27, 1806-1809.	0.5	4
39	Drug Approvals in Hepatocellular Carcinoma—Filling the Nonexistent Gap?. JAMA Oncology, 2021, 7, 173.	3.4	3
40	Level of Scientific Evidence Underlying the National Comprehensive Cancer Network Clinical Practice Guidelines for Hematologic Malignancies: Are We Moving Forward?. Oncology, 2021, 35, 390-396.	0.4	3
41	Incidence of and Risk Factors for Venous Thromboembolism Among Hospitalized Patients with Cancer and COVID-19: Report from the COVID-19 and Cancer Consortium (CCC19) Registry. Blood, 2020, 136, 56-58.	0.6	3
42	Clinical Trial End Points in Severe COVID-19. Mayo Clinic Proceedings, 2020, 95, 1578-1580.	1.4	2
43	COVID-19 in Older Individuals with Cancer: Problem and Potential Solutions. Cancer Investigation, 2021, 39, 214-216.	0.6	2
44	Clinical Trial Access in Low- and Middle-Income Countries: A Case Study on India. Cancer Investigation, 2021, 39, 685-689.	0.6	2
45	Secondary Immune Thrombocytopenic Purpura in Renal Cell Cancer: A Paraneoplastic Syndrome. Cureus, 2019, 11, e4398.	0.2	2
46	Calvarial osteomyelitis and intracranial extension post-Mohs micrographic surgery. BMJ Case Reports, 2018, 2018, bcr-2018-224861.	0.2	1
47	Zieve's Syndrome: an Unusual Cause of Anemia. SN Comprehensive Clinical Medicine, 2020, 2, 349-354.	0.3	0
48	The Great Breast Cancer Screening Conundrum. Indian Journal of Medical and Paediatric Oncology, 2021, 42, 376-379.	0.1	0
49	The Sustainability of Price Dynamics in Precision Hematology. Blood, 2021, 138, 114-114.	0.6	0
50	Level of Scientific Evidence Underlying Recommendations from the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Hematologic Malignancies: Are We Moving Forward?. Blood, 2020, 136, 32-32.	0.6	0
51	Management of Non-Small Cell Lung Cancer: Updates from the European Lung Cancer Congress 2022. Cancer Investigation, 2022, 40, 577-589.	0.6	0